131 related articles for article (PubMed ID: 7932546)
41. Structure of HIV-1 protease with KNI-272: a transition state mimetic inhibitor containing allophenylnorstatine.
Baldwin ET; Bhat TN; Gulnik S; Liu B; Kiso Y; Mitsuya H; Erickson JW
Adv Exp Med Biol; 1995; 362():445-9. PubMed ID: 8540355
[No Abstract] [Full Text] [Related]
42. L-735,524: the design of a potent and orally bioavailable HIV protease inhibitor.
Dorsey BD; Levin RB; McDaniel SL; Vacca JP; Guare JP; Darke PL; Zugay JA; Emini EA; Schleif WA; Quintero JC
J Med Chem; 1994 Oct; 37(21):3443-51. PubMed ID: 7932573
[TBL] [Abstract][Full Text] [Related]
43. Nonpeptidic HIV protease inhibitors: 4-hydroxy-pyran-2-one inhibitors with functional tethers to P1 phenyl ring to reach S3 pocket of the enzyme.
Vara Prasad J; Tummino PJ; Ferguson D; Saunders J; Vander Roest S; McQuade TJ; Heldsinger A; Reyner EL; Stewart BH; Guttendorf RJ; Para KS; Lunney EA; Gracheck SJ; Domagala JM
Biochem Biophys Res Commun; 1996 Apr; 221(3):815-20. PubMed ID: 8630044
[TBL] [Abstract][Full Text] [Related]
44. Nonpeptidic HIV protease inhibitors: 6-alkyl-5,6-dihydropyran-2-ones possessing a novel and achiral 3-(2-t-butyl-5-methyl-4-sulfamate)phenylthio moiety.
Vara Prasad JV; Markoski LJ; Boyer FE; Domagala JM; Ellsworth EL; Gajda C; Hagen SE; Tait BD; Lunney EA; Tummino PJ; Ferguson D; Holler T; Hupe D; Nouhan C; Gracheck SJ; VanderRoest S; Saunders J; Iyer K; Sinz M
Bioorg Med Chem Lett; 1999 Aug; 9(15):2217-22. PubMed ID: 10465549
[TBL] [Abstract][Full Text] [Related]
45. [Current status of HIV protease inhibitors].
Yang QG; He XC; Bai DL
Yao Xue Xue Bao; 2005 May; 40(5):389-94. PubMed ID: 16220778
[No Abstract] [Full Text] [Related]
46. An orally bioavailable pyrrolinone inhibitor of HIV-1 protease: computational analysis and X-ray crystal structure of the enzyme complex.
Smith AB; Hirschmann R; Pasternak A; Yao W; Sprengeler PA; Holloway MK; Kuo LC; Chen Z; Darke PL; Schleif WA
J Med Chem; 1997 Aug; 40(16):2440-4. PubMed ID: 9258349
[No Abstract] [Full Text] [Related]
47. Unexpected binding mode of a cyclic sulfamide HIV-1 protease inhibitor.
Bäckbro K; Löwgren S; Osterlund K; Atepo J; Unge T; Hultén J; Bonham NM; Schaal W; Karlén A; Hallberg A
J Med Chem; 1997 Mar; 40(6):898-902. PubMed ID: 9083478
[TBL] [Abstract][Full Text] [Related]
48. Fluorogenic Assay for Inhibitors of HIV-1 Protease with Sub-picomolar Affinity.
Windsor IW; Raines RT
Sci Rep; 2015 Aug; 5():11286. PubMed ID: 26261098
[TBL] [Abstract][Full Text] [Related]
49. A preference-based free-energy parameterization of enzyme-inhibitor binding. Applications to HIV-1-protease inhibitor design.
Wallqvist A; Jernigan RL; Covell DG
Protein Sci; 1995 Sep; 4(9):1881-903. PubMed ID: 8528086
[TBL] [Abstract][Full Text] [Related]
50. Prediction of HIV-1 protease inhibitory activity of 4-hydroxy-5,6-dihydropyran-2-ones: QSAR study.
Ravichandran V; Mourya VK; Agrawal RK
J Enzyme Inhib Med Chem; 2011 Apr; 26(2):288-94. PubMed ID: 20735159
[TBL] [Abstract][Full Text] [Related]
51. Inorganic polyhedral metallacarborane inhibitors of HIV protease: a new approach to overcoming antiviral resistance.
Kozísek M; Cígler P; Lepsík M; Fanfrlík J; Rezácová P; Brynda J; Pokorná J; Plesek J; Grüner B; Grantz Sasková K; Václavíková J; Král V; Konvalinka J
J Med Chem; 2008 Aug; 51(15):4839-43. PubMed ID: 18598016
[TBL] [Abstract][Full Text] [Related]
52. Efficiency of a second-generation HIV-1 protease inhibitor studied by molecular dynamics and absolute binding free energy calculations.
Lepsík M; Kríz Z; Havlas Z
Proteins; 2004 Nov; 57(2):279-93. PubMed ID: 15340915
[TBL] [Abstract][Full Text] [Related]
53. Optimization and computational evaluation of a series of potential active site inhibitors of the V82F/I84V drug-resistant mutant of HIV-1 protease: an application of the relaxed complex method of structure-based drug design.
Perryman AL; Lin JH; Andrew McCammon J
Chem Biol Drug Des; 2006 May; 67(5):336-45. PubMed ID: 16784458
[TBL] [Abstract][Full Text] [Related]
54. Peptide aldehydes as inhibitors of HIV protease.
Sarubbi E; Seneci PF; Angelastro MR; Peet NP; Denaro M; Islam K
FEBS Lett; 1993 Mar; 319(3):253-6. PubMed ID: 8458418
[TBL] [Abstract][Full Text] [Related]
55. Small dipeptide-based HIV protease inhibitors containing the hydroxymethylcarbonyl isostere as an ideal transition-state mimic.
Kiso Y; Matsumoto H; Mizumoto S; Kimura T; Fujiwara Y; Akaji K
Biopolymers; 1999; 51(1):59-68. PubMed ID: 10380353
[TBL] [Abstract][Full Text] [Related]
56. Calculation of relative differences in the binding free energies of HIV1 protease inhibitors: a thermodynamic cycle perturbation approach.
Reddy MR; Varney MD; Kalish V; Viswanadhan VN; Appelt K
J Med Chem; 1994 Apr; 37(8):1145-52. PubMed ID: 8164256
[TBL] [Abstract][Full Text] [Related]
57. Constructing Interconsistent, Reasonable, and Predictive Models for Both the Kinetic and Thermodynamic Properties of HIV-1 Protease Inhibitors.
Qu S; Huang S; Pan X; Yang L; Mei H
J Chem Inf Model; 2016 Oct; 56(10):2061-2068. PubMed ID: 27624663
[TBL] [Abstract][Full Text] [Related]
58. Enamino-oxindole HIV protease inhibitors.
Eissenstat M; Guerassina T; Gulnik S; Afonina E; Silva AM; Ludtke D; Yokoe H; Yu B; Erickson J
Bioorg Med Chem Lett; 2012 Aug; 22(15):5078-83. PubMed ID: 22749283
[TBL] [Abstract][Full Text] [Related]
59. Chiral squaramides as highly enantioselective catalysts for Michael addition reactions of 4-hydroxycoumarins and 4-hydroxypyrone to beta,gamma-unsaturated alpha-keto esters.
Xu DQ; Wang YF; Zhang W; Luo SP; Zhong AG; Xia AB; Xu ZY
Chemistry; 2010 Apr; 16(14):4177-80. PubMed ID: 20229539
[No Abstract] [Full Text] [Related]
60. Revealing interaction mode between HIV-1 protease and mannitol analog inhibitor.
Yan GW; Chen Y; Li Y; Chen HF
Chem Biol Drug Des; 2012 Jun; 79(6):916-25. PubMed ID: 22296911
[TBL] [Abstract][Full Text] [Related]
[Previous] [Next] [New Search]
